Delivery Order SPE2DB22D3501-SPE2DB24FTJ35

Award Date 10/31/23
Potential Completion Date 11/1/23
Potential Value $7.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,179.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which has a completion date of March 14, 2025, is for the delivery of Ondansetron ODT 8 mg tablets in quantities of 30s. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $1,196.53, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron ODT 4 mg Tablets in quantities of 30. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,739.22 firm fixed price delivery order is for the supply of Ondansetron ODT 8 mg tablets. The contract has an ultimate completion date of September 20, 2023. This award is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award, valued at $9,996.23, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,566,134,913 units of Ondansetron ODT 4 mg Tablets in 30-count packages. This award is a delivery order under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA, which serves as a primary vehicle for...
This federal contract award, valued at $27,519.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of 4,568,060,760 units of the medication Ondansetron ODT 8 mg tablet, with a performance period ending on April 29, 2025. This contract is a delivery order and is priced on a firm-fixed-price basis. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Ondansetron ODT 8 mg tablets. The contract has a firm fixed price of $1,271.26 and an ultimate completion date of October 9, 2024. This is a delivery order contract, which is likely part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 through...
This federal contract award, valued at $1,538.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron ODT 4 mg Tablets in quantities of 30 per tablet, with a completion date of February 5, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $48,748.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,563,250,472 units of the drug Ondansetron ODT 4 mg tablet, with a performance period through January 8, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
This federal contract award, valued at $2,222.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,955,862 units of the medication Ondansetron ODT 8 mg Tablet, with an ultimate completion date of April 18, 2025. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $47,244.54, is for the delivery of Ondansetron ODT 8 MG Tablets in quantities of 30. It is a firm fixed price delivery order contract with a completion date of March 31, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FTJ35
    Delivery Order

This federal contract award, valued at $7,120.13, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron ODT 8 mg Tablets to support federal healthcare programs.

The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition.

Generated 5/12/25, 10:25 AM